Orion’s cancer reset bears fruit
Already boasting the marketed Nubeqa, Orion licenses its next-biggest prostate cancer hope to Merck & Co.
Biogen leads the amyotrophic lateral sclerosis hopefuls
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
Amylyx provides hope in amyotrophic lateral sclerosis
Amylyx believes it has found a disease-modifying therapy in AMX0035, as other key readouts approach.
Biogen leads the way in renewed amyotrophic lateral sclerosis push
The company has quietly emerged as the key player to watch in an area that has seen several setbacks of late.
Asco-GU 2019 – Bayer and Orion have their work cut out with darolutamide
Results of the prostate cancer project’s pivotal Aramis trial, already known to be positive, are presented for the first time.
Titan could give Erleada a fighting chance
But Erleada, Johnson & Johnson’s next-gen prostate cancer therapy, still needs to outperform the incumbent, Zytiga.
Upcoming events – Pivotal data readouts for Galapagos and Bayer
Galapagos and Bayer/Orion will both report phase III data this quarter – the former with filgotinib in arthritis and the latter with darolutamide in prostate cancer.
